Theriva Biologics, Inc.
TOVX · AMEX
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $12,031 | $14,311 | $11,723 | $7,800 |
| G&A Expenses | $7,396 | $7,156 | $6,998 | $6,474 |
| SG&A Expenses | $7,396 | $7,780 | $7,567 | $6,474 |
| Sales & Mktg Exp. | $0 | $624 | $569 | $0 |
| Other Operating Expenses | $6,919 | -$660 | $2,291 | $0 |
| Operating Expenses | $26,346 | $21,431 | $21,581 | $14,274 |
| Operating Income | -$26,346 | -$21,431 | -$21,581 | -$14,274 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $693 | $1,442 | $471 | $6 |
| Pre-Tax Income | -$25,653 | -$19,989 | -$21,110 | -$14,268 |
| Tax Expense | $0 | -$1,640 | -$1,425 | $0 |
| Net Income | -$25,653 | -$18,349 | -$19,685 | -$14,267 |
| % Margin | – | – | – | – |
| EPS | -19.03 | -28.49 | -32.66 | -1.9 |
| % Growth | 33.2% | 12.8% | -1,618.9% | – |
| EPS Diluted | -19.03 | -28.48 | -32.66 | -1.9 |
| Weighted Avg Shares Out | 1,348 | 644 | 613 | 12,188 |
| Weighted Avg Shares Out Dil | 1,348 | 644 | 613 | 12,188 |
| Supplemental Information | – | – | – | – |
| Interest Income | $697 | $1,439 | $512 | $6 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $137 | $135 | $85 | $87 |
| EBITDA | -$19,290 | -$21,956 | -$19,205 | -$14,187 |
| % Margin | – | – | – | – |